A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.
Saved in:
| Title: | A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer. |
|---|---|
| Authors: | Hamm C; University of Windsor, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Western University, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca.; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA. caroline.hamm@wrh.on.ca.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada. caroline.hamm@wrh.on.ca., Fifield BA; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada., Kay A; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada., Kulkarni S; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada., Gupta R; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada., Mathews J; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Western University, Windsor, ON, N9B 3P4, Canada., Ferraiuolo RM; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada.; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA., Al-Wahsh H; University of Calgary, Calgary, AB, Canada., Mailloux E; University of Windsor, Windsor, ON, N9B 3P4, Canada.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada., Hussein A; University of Windsor, Windsor, ON, N9B 3P4, Canada., Porter LA; University of Windsor, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca.; Windsor Cancer Research Group, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca.; WE-SPARK Health Institute, Windsor, ON, N9B 3P4, Canada. lporter@uwindsor.ca. |
| Source: | Medical oncology (Northwood, London, England) [Med Oncol] 2022 Feb 01; Vol. 39 (4), pp. 49. Date of Electronic Publication: 2022 Feb 01. |
| Publication Type: | Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
